Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention (PCI).
We aimed to estimate the utility of panel-based pharmacogenetic testing of patients undergoing percutaneous coronary intervention (PCI). Utilization of Clinical Pharmacogenetic Implementation Consortium (CPIC) level A/B drugs after PCI was estimated in a national sample of IBM MarketScan beneficiaries. Genotype data from University of Florida (UF) PCI patients (n=211) were used to project genotype-guided opportunities among MarketScan beneficiaries with at least one- (N=105,547) and five-(N=12,462) years of follow up data. The actual incidence of genotype-guided prescribing opportunities was determined among UF patients. In MarketScan, 50.0% (52,799/105,547) over one year and 68.0% (8,473/12,462) over five years had ≥ one CPIC A/B drug besides antiplatelet therapy prescribed, with a projected incidence of genotype-guided prescribing opportunities of 39% at one year and 52% at five years. Genotype-guided prescribing opportunities occurred in 32% of UF patients. Projected and actual incidence of genotype-guided opportunities among two cohorts support the utility of panel-based testing among PCI patients.